Retension Pharmaceuticals, Inc. RTSN
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Net Income | -11.94M | -- | -- | -- | |
| Total Depreciation and Amortization | -- | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 269.50K | -- | -- | -- | |
| Change in Net Operating Assets | -220.50K | -- | -- | -- | |
| Cash from Operations | -11.89M | -- | -- | -- | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -- | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 3.30K | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | 7.12M | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -1.00K | -- | -- | -- | |
| Cash from Financing | 7.12M | -- | -- | -- | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -4.77M | -- | -- | -- | |